UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) DELAWARE 84-1375299 (State or other jurisdiction (IRS Employer of incorporat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _______ to _________ Commission File No. 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1375299 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) DELAWARE 84-1375299 (State or other jurisdiction (IRS Employer of incorporati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) DELAWARE 84-1375299 (State or other jurisdiction (IRS Employer of incorporat ...

[PART I](index=7&type=section&id=PART%20I) [Business](index=7&type=section&id=Item%201.%20Business) SINTX Technologies specializes in silicon nitride for biomedical, industrial, and antipathogenic applications, focusing on OEM manufacturing and R&D for external partners - SINTX Technologies, a 25-year-old advanced ceramics company, focuses on biomedical, industrial, and antipathogenic applications, shifting to OEM manufacturing and R&D for external partners[28](index=28&type=chunk) - The company's core business utilizes proprietary silicon nitride for **biomedical** (spinal implants, bone growth), **industrial** (aerospace, armor), and **antipathogenic** (SARS-CoV-2 inactivation) applications[29](index=29&type=chunk)[31](index=31&type=chunk)[33](index=33&type=chunk) - Silicon nitride is produced in various forms, including solid, porous, powder, composites, and coatings, enabling diverse applications[37](index=37&type=chunk)[40](index=40&type=chunk) - In 2021, SINTX entered the ceramic armor market by acquiring B4C, LLC assets and establishing SINTX Armor, Inc. for boron carbide and composite armor development[32](index=32&type=chunk)[44](index=44&type=chunk) - The company relies on fourteen U.S. patents, trade secrets, and know-how, with the core patent expiring in June 2022 and newer patents focusing on antibacterial properties[56](index=56&type=chunk)[57](index=57&type=chunk)[60](index=60&type=chunk) - Medical device products are subject to extensive FDA regulation in the U.S., requiring 510(k) clearance or PMA, and international compliance like the EU CE Mark[73](index=73&type=chunk)[74](index=74&type=chunk)[83](index=83&type=chunk) [Risk Factors](index=23&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant risks including persistent net losses, heavy reliance on CTL Medical, intense competition, regulatory hurdles, capital needs, and Nasdaq delisting concerns - The company has a history of net losses, with **$8.8 million** in 2021 and **$7.0 million** in 2020, and an accumulated deficit of **$249.9 million** as of December 31, 2021[109](index=109&type=chunk) - A significant portion of revenue depends on CTL Medical's sales of spinal fusion products, with no minimum purchase obligations under their 10-year agreement[113](index=113&type=chunk)[118](index=118&type=chunk) - The company faces intense competition from larger orthopedic companies like Medtronic, DePuy Synthes, and Stryker, possessing greater financial resources[114](index=114&type=chunk)[115](index=115&type=chunk) - Additional financing is required to fund product development and commercialization; failure to secure it could lead to program delays or elimination[139](index=139&type=chunk) - The company lacks patent protection for the composition of matter of its solid silicon nitride, potentially allowing competitors to develop similar formulations[174](index=174&type=chunk) - On January 3, 2022, Nasdaq issued a delisting notice due to the stock price falling below **$1.00** for 30 consecutive days; failure to comply by July 5, 2022, could result in delisting[197](index=197&type=chunk) [Unresolved Staff Comments](index=45&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) The company reports no unresolved staff comments from the SEC - Not applicable[200](index=200&type=chunk) [Properties](index=45&type=section&id=Item%202.%20Properties) SINTX Technologies operates two leased facilities in Salt Lake City, Utah: a 29,534 sq ft corporate/manufacturing site and a 10,936 sq ft Armor business facility - The company leases a **29,534 sq. ft.** corporate office and manufacturing facility in Salt Lake City, UT, with the lease expiring in December 2024[201](index=201&type=chunk) - A separate **10,936 sq. ft.** facility is leased in Salt Lake City, UT, for the Armor business, with its lease expiring in October 2031[201](index=201&type=chunk) [Legal Proceedings](index=45&type=section&id=Item%203.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings - The company is currently not a party to any material legal proceedings[203](index=203&type=chunk) [Mine Safety Disclosures](index=45&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - This item does not apply to the company's business[204](index=204&type=chunk) [PART II](index=46&type=section&id=PART%20II) [Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=46&type=section&id=Item%205.%20Market%20for%20Registrant%27s%20Common%20Equity%2C%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) The company's common stock trades on NASDAQ under 'SINT', experiencing price volatility, with no history or future plans for cash dividends - The company's common stock trades on The NASDAQ Capital Market under the symbol **"SINT"**[207](index=207&type=chunk) Quarterly High and Low Stock Prices (2021) | Quarter | High ($) | Low ($) | | :--- | :--- | :--- | | First | 3.44 | 1.51 | | Second | 2.06 | 1.23 | | Third | 2.04 | 1.22 | | Fourth | 1.36 | 0.59 | - The company has not declared or paid dividends since inception and does not plan to pay cash dividends in the foreseeable future[209](index=209&type=chunk) [Selected Financial Data](index=46&type=section&id=Item%206.%20Selected%20Financial%20Data) This item is not applicable as the company qualifies as a smaller reporting company - Not applicable[210](index=210&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=47&type=section&id=Item%207.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) SINTX reported an increased net loss of **$8.8 million** in 2021, driven by higher R&D and sales/marketing expenses, with cash decreasing to **$14.3 million**, though management expects sufficient capital through March 2023 Results of Operations (in thousands) | | 2021 | 2020 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Product revenue | $606 | $594 | $12 | 2% | | Gross profit | $157 | $119 | $38 | 32% | | Research and development | $5,886 | $4,808 | $1,078 | 22% | | General and administrative | $3,603 | $3,132 | $471 | 15% | | Sales and marketing | $1,288 | $683 | $605 | 89% | | Loss from operations | $(10,620) | $(8,504) | $(2,116) | 25% | | Net loss | $(8,775) | $(7,029) | $(1,746) | 25% | - R&D expenses increased by **$1.1 million** (**22%**) due to heightened activity in developing new technologies and products[233](index=233&type=chunk) - Sales and marketing expenses rose by **$0.6 million** (**89%**) due to increased efforts to generate interest in potential new product lines[235](index=235&type=chunk) - The company's continuation as a going concern depends on increasing sales or raising additional capital; management believes existing capital is sufficient through March 2023[239](index=239&type=chunk)[245](index=245&type=chunk) Cash Flow Summary (in thousands) | | 2021 | 2020 | | :--- | :--- | :--- | | Net cash used in operating activities | $(10,132) | $(9,112) | | Net cash provided by (used in) investing activities | $(1,651) | $1,751 | | Net cash provided by financing activities | $705 | $30,925 | - Cash from financing activities significantly decreased from **$30.9 million** in 2020 to **$0.7 million** in 2021, reflecting reduced capital raising efforts[251](index=251&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=58&type=section&id=Item%207A.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This item is not applicable to the company - Not applicable[276](index=276&type=chunk) [Financial Statements and Supplementary Data](index=58&type=section&id=Item%208.%20Financial%20Statements%20and%20Supplementary%20Data) This section includes audited consolidated financial statements and Tanner LLC's unqualified report, highlighting warrant valuation as a critical audit matter due to complex judgments - The consolidated financial statements are included at the end of the report, beginning on page F-1[277](index=277&type=chunk) - Tanner LLC's independent auditor's report identified the valuation of warrants as derivative liabilities as a Critical Audit Matter due to complex fair value estimation judgments[389](index=389&type=chunk)[390](index=390&type=chunk) [Changes in and Disagreements With Accountants on Accounting and Financial Disclosure](index=58&type=section&id=Item%209.%20Changes%20in%20and%20Disagreements%20With%20Accountants%20on%20Accounting%20and%20Financial%20Disclosure) The company reports no changes in or disagreements with its accountants regarding accounting and financial disclosure - None[278](index=278&type=chunk) [Controls and Procedures](index=58&type=section&id=Item%209A.%20Controls%20and%20Procedures) As of December 31, 2021, management concluded that the company's disclosure controls and internal control over financial reporting were effective - Management concluded that the company's disclosure controls and procedures were effective as of December 31, 2021[280](index=280&type=chunk) - Based on the COSO framework, management determined the company's internal control over financial reporting was effective as of December 31, 2021[285](index=285&type=chunk)[286](index=286&type=chunk) [Other Information](index=59&type=section&id=Item%209B.%20Other%20Information) There is no information to report under this item - None[288](index=288&type=chunk) [Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.](index=59&type=section&id=Item%209C.%20Disclosure%20Regarding%20Foreign%20Jurisdictions%20that%20Prevent%20Inspections.) This item is not applicable to the company - None[289](index=289&type=chunk) [PART III](index=60&type=section&id=PART%20III) [Directors, Executive Officers and Corporate Governance](index=60&type=section&id=Item%2010.%20Directors%2C%20Executive%20Officers%20and%20Corporate%20Governance) The company's five-member Board, with four independent directors and a staggered structure, maintains three independent committees and has adopted a Code of Business Conduct - The Board of Directors comprises five members, including B. Sonny Bal, M.D. as Chairman, President, and CEO[292](index=292&type=chunk) - The Board is divided into three staggered classes, with four of the five directors deemed independent under Nasdaq rules[308](index=308&type=chunk)[309](index=309&type=chunk) - The Board maintains three permanent committees—Audit, Compensation, and Governance and Nominating—all composed of independent directors[310](index=310&type=chunk)[312](index=312&type=chunk) - The company has adopted a Code of Business Conduct, available on its website[321](index=321&type=chunk) [Executive Compensation](index=66&type=section&id=Item%2011.%20Executive%20Compensation) This section details executive compensation, including CEO B. Sonny Bal's **$483,087** total compensation in 2021, 401(k) matching, and change-in-control severance provisions 2021 Summary Compensation Table | Name and Principal Position | Year | Salary ($) | Bonus ($) | Option Awards ($) | Total Compensation ($) | | :--- | :--- | :--- | :--- | :--- | :--- | | B. Sonny Bal, CEO | 2021 | 400,000 | 40,989 | 38,291 | 483,087 | | David O'Brien, COO | 2021 | 300,000 | 25,279 | 28,053 | 370,219 | - Upon a qualifying termination following a change in control, executives receive a lump sum payment equal to two times their highest annual salary (including bonus) and full vesting of all outstanding equity awards[332](index=332&type=chunk) - The company offers a 401(k) plan with a company match on employee contributions[329](index=329&type=chunk) 2021 Non-Employee Director Compensation | Name | Fees Earned or Paid in Cash ($) | Option Awards ($) | Total ($) | | :--- | :--- | :--- | :--- | | David W. Truetzel | 120,500 | 30,520 | 151,020 | | Jeffrey S. White | 40,500 | 30,520 | 71,020 | | Eric A. Stookey | 40,000 | 30,520 | 70,520 | | Mark Froimson | 40,500 | 29,762 | 70,262 | [Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](index=71&type=section&id=Item%2012.%20Security%20Ownership%20of%20Certain%20Beneficial%20Owners%20and%20Management%20and%20Related%20Stockholder%20Matters) As of March 1, 2022, the company had **24,713,574** common shares outstanding, with no known 5% beneficial owners and management collectively owning approximately **2%** - As of March 1, 2022, **24,713,574** shares of common stock were issued and outstanding[352](index=352&type=chunk) - No stockholders are known by the company to beneficially own more than **5%** of its common stock[355](index=355&type=chunk) - All executive officers and directors as a group beneficially own **484,853** shares, representing approximately **2%** of the outstanding common stock[355](index=355&type=chunk) [Certain Relationships and Related Transactions, and Director Independence](index=72&type=section&id=Item%2013.%20Certain%20Relationships%20and%20Related%20Transactions%2C%20and%20Director%20Independence) The company has not engaged in material related party transactions since 2022, excluding standard compensation, and has a policy for Audit Committee review and approval - No material related party transactions have occurred since January 1, 2022, other than standard compensation and indemnification agreements for directors and officers[356](index=356&type=chunk) - The company has a policy requiring Audit Committee review, approval, or ratification of all related party transactions[357](index=357&type=chunk) [Principal Accountant Fees and Services](index=73&type=section&id=Item%2014.%20Principal%20Accountant%20Fees%20and%20Services) Tanner LLC served as the principal accounting firm, with total fees of **$165,423** in 2021 and **$312,152** in 2020, and all services pre-approved by the Audit Committee Principal Accountant Fees (in thousands) | | Year Ended Dec 31, 2021 | Year Ended Dec 31, 2020 | | :--- | :--- | :--- | | Audit fees | $127,064 | $163,434 | | Audit related fees | $38,359 | $148,718 | | **Total Fees** | **$165,423** | **$312,152** | - The Audit Committee's charter requires pre-approval of all audit and non-audit services provided by the independent auditors[365](index=365&type=chunk) [PART IV](index=74&type=section&id=PART%20IV) [Exhibits and Financial Statement Schedules](index=74&type=section&id=Item%2015.%20Exhibits%20and%20Financial%20Statement%20Schedules) This section indexes consolidated financial statements and lists all exhibits, including key agreements like the CTL Medical Asset Purchase Agreement and corporate governance documents - This item references the Index to Consolidated Financial Statements, beginning on page F-1[367](index=367&type=chunk) - An extensive list of exhibits is provided, including key agreements like the Asset Purchase Agreement with CTL Medical, corporate governance documents, and financing agreements[370](index=370&type=chunk)[372](index=372&type=chunk)[374](index=374&type=chunk) [Form 10-K Summary](index=80&type=section&id=Item%2016.%20Form%2010-K%20Summary) There is no summary provided under this item - None[376](index=376&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) DELAWARE 84-1375299 (State or other jurisdiction (IRS Employer of incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) DELAWARE 84-1375299 (State or other jurisdiction (IRS Employer of incorporati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) DELAWARE 84-1375299 (State or other jurisdiction (IRS Employer of incorp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K [X] Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2020 or [ ] Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _______ to _________ Commission File No. 001-33624 SINTX Technologies, Inc. (Exact name of registrant as specified in its charter) Delaware 84-1375299 (State or other juris ...